Standout Papers
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis (2006)
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis (2008)
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis (2006)
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial (2012)
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (2012)
Immediate Impact
1 by Nobel laureates 14 from Science/Nature 87 standout
Citing Papers
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Antisense technology: A review
2021 Standout
Works of Michael Panzara being referenced
O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
2019
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
2006 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michael Panzara | 7387 | 3237 | 3321 | 78 | 10.0k | |
| Alfred Sandrock | 5213 | 2914 | 1537 | 59 | 8.2k | |
| J. Theodore Phillips | 5067 | 2450 | 1665 | 97 | 7.3k | |
| Hillel Panitch | 5530 | 1568 | 2194 | 95 | 8.1k | |
| Hans-Peter Hartung | 5071 | 1668 | 1827 | 82 | 7.4k | |
| D. A. S. Compston | 7573 | 1921 | 3467 | 179 | 13.3k | |
| Stephen L. Hauser | 5291 | 1770 | 2965 | 96 | 9.9k | |
| Sandra Vukusic | 6690 | 1061 | 1396 | 167 | 8.9k | |
| K C Gatter | 6654 | 6040 | 2653 | 105 | 14.7k | |
| Elizabeth Fisher | 5340 | 1185 | 824 | 108 | 7.0k | |
| Paolo A. Muraro | 3704 | 1394 | 1883 | 126 | 5.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...